At a glance
ClinicalIndex Comparison Record- ✓AML in first, second, or greater remission
- ✓AML in early relapse with <30% marrow blasts
- ✓ALL in second or greater complete remission
- ✓High-risk ALL in first complete remission (t(4;11), t(9;22), t(8;14), extreme hyperleukocytosis with WBC >500 K/ml, or failure to achieve CR after standard induction)
- ✕Life expectancy <3 months with therapy
- ✕ECOG performance status >2 or Lansky Scale <70%
- ✕Active infection (soft tissue, sinus, dental, fungal, or hepatitis)
- ✕HIV-positive
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors
In Brief
A Phase 2 clinical trial evaluating busulfan, cyclophosphamide, and 4 other interventions for Leukemia and 3 related conditions. Completed, enrolled 34 participants across 1 site.
Detailed Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well giving chemotherapy with or without radiation therapy followed by donor stem cell transplant works in treating patients with hematologic cancer.
Study Details
Timeline
Interventions
Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
Given IV
Given IV
Patients undergo total body irradiation
infusion